1
=
-
Revolution Medicines, Inc. Common Stock
As of May 21, 2026 at 10:03 UTC
Chart
About Revolution Medicines, Inc. Common Stock
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Market Statistics
Trading Metrics
How to Buy RVMD
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy RVMD
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesLaw firm Bragar Eagel & Squire is investigating Erasca, Inc. following a patent infringement allegation from Revolution Medicines regarding the company's ERAS-0015 drug candidate. The disclosure triggered a significant stock price decline of approximately 48%, dropping from $19.15 to $9.90 per share on April 28, 2026. The firm is seeking stockholders who suffered losses to discuss potential legal claims.
Revolution Medicines' experimental pancreatic cancer drug daraxonrasib has generated significant demand from cancer centers following FDA approval of its expanded access program in May. The Phase 3 RASolute 302 trial showed the drug doubled overall survival to 13.2 months versus 6.7 months for standard chemotherapy. However, the company faces operational challenges managing the compassionate use process, and RVMD stock declined 3.47% despite the positive clinical results.
Law firm Bragar Eagel & Squire is investigating Erasca, Inc. following a patent infringement allegation from Revolution Medicines regarding the company's ERAS-0015 drug candidate. The disclosure triggered a significant stock price decline of approximately 48%, dropping from $19.15 to $9.90 per share on April 28, 2026. The firm is seeking stockholders who suffered losses to discuss potential legal claims.
The Schall Law Firm is investigating Erasca, Inc. (NASDAQ: ERAS) for potential securities law violations following the company's disclosure on April 28, 2026, that it received a patent infringement letter from Revolution Medicines regarding its ERAS-0015 drug candidate, along with trade secret misappropriation allegations. The announcement triggered a 48.3% stock price decline on the same day.
Revolution Medicines announced the publication of Phase 1/2 clinical trial data for daraxonrasib in the New England Journal of Medicine, showing promising antitumor activity and durable responses in previously treated metastatic RAS mutant pancreatic cancer. The data supported initiation of the Phase 3 RASolute 302 trial, which recently reported unprecedented overall survival benefits compared to standard chemotherapy.